 AstraZeneca PLCs LON:AZN expects to complete its 27.5bn acquisition of rare disease specialist Alexion Pharmaceuticals Inc next week after getting the go-ahead from UK authorities. The UK Competition and Markets Authority said this morning that it cleared the proposed deal, deciding not to refer it to a Phase 2 investigation. 